Press Releases MaxCyte, Inc.

Equities

MXCT

US57777K1060

Delayed London S.E. Other stock markets 09:31:17 2024-04-29 am EDT			5-day change	1st Jan Change
291 ^GBX	-1.36%		-7.62%	-17.45%

Apr. 02	MaxCyte inks deal with Be Bio; Orcadian firms farmout	AN
Apr. 02	MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024	Apr. 10	GL
MaxCyte, Inc. - Exercise of options and PDMR dealing	Apr. 03	AQ
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B cell Medicines	Apr. 03	AQ
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)	Apr. 02	GL
MaxCyte, Inc. - Grant of Options, RSUs and PSUs and PDMR Dealing	Mar. 21	AQ
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance	Mar. 12	GL
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	Mar. 06	AQ
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results	Mar. 04	GL
MaxCyte, Inc. - Exercise of options and PDMR dealing	Mar. 01	AQ
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences	Feb. 09	GL
MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences	Feb. 09	AQ
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers	Jan. 31	AQ
MaxCyte announces filing of Form 8-K	Jan. 30	AQ
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers	Jan. 30	GL
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs	Jan. 23	GL
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs	Jan. 23	AQ
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results	Jan. 08	GL
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline	Jan. 03	AQ
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline	Jan. 03	GL
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director	Jan. 02	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MaxCyte, Inc.

Equities

MXCT

US57777K1060

Press Releases

Filters